Format

Send to

Choose Destination
Oncoimmunology. 2013 Feb 1;2(2):e22891.

ImmTACs: Novel bi-specific agents for targeted cancer therapy.

Author information

1
Immunocore Ltd; Abingdon, UK.

Abstract

Our expanding knowledge of the immune system is guiding a new era of targeted anticancer therapies. Here, we describe our recent work on a novel class of anticancer agents termed ImmTACs. These molecules combine the power of picomolar-affinity TCR-based antigen recognition with the immune-activating potential of an anti-CD3 antibody fragment, to potently redirect T-cell killing to tumor cells.

KEYWORDS:

CD3; ImmTAC; T cell receptor; immunotherapy; thymic selection

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center